Identification of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors for the Treatment of Colorectal Cancer.

ACS Medicinal Chemistry Letters
Yifei YangJinpei Zhou

Abstract

Bromodomain-containing protein 4 (Brd4) plays a critical regulatory role in gene transcription that has been recently recognized as a promising strategy for cancer therapy. Based on the BRD4 protein containing two tandem bromodomain structures, BD1 and BD2, we designed and synthesized a series of 3,5-dimethylisoxazole derivative dimers targeting both bromodomains simultaneously to enhance protein binding potency. Among them, compound 22 significantly inhibited the proliferation of colorectal cancer cells HCT116 (IC50 = 162 nM), with a 20-fold increase in antiproliferative activity compared to inhibitor 14. The results of WesternBlot showed that compound 22 could down-regulate c-MYC protein levels and up-regulate HEXIM1 expression and modulate apoptosis through intrinsic pathways. In addition, compound 22 exhibited outstanding antitumor efficacy in the CT-26 tumor mouse model with a tumor suppression rate of 56.1%. Taken together, 3,5-dimethylisoxazole derivative dimer 22 has remarkable protein inhibitory effect and antitumor activity in vitro and in vivo. A protein binding model of compound 22 is being further analyzed, which will facilitate the development of bivalent BRD4 inhibitors and probe the biological function of BRD4.

References

Sep 6, 2011·Cell·Jake E DelmoreConstantine S Mitsiades
Sep 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jennifer A MertzRobert J Sims
Oct 25, 2011·Annual Review of Pathology·Christopher A French
Jan 7, 2014·PloS One·Kevin G McLurePeter R Young
Apr 2, 2014·Biochimica Et Biophysica Acta·Roberto SanchezMing-Ming Zhou
Apr 23, 2014·Nature Reviews. Drug Discovery·Panagis Filippakopoulos, Stefan Knapp
Jan 28, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michela BoiFrancesco Bertoni
Jun 9, 2015·Chemistry & Biology·Jing LuCraig M Crews
Oct 24, 2015·Chemical Reviews·Guangtao ZhangMing-Ming Zhou
Jan 13, 2016·Angewandte Chemie·Momar Toure, Craig M Crews
Nov 4, 2016·Molecular Cancer Therapeutics·Garrett W RhyasenHuawei Chen
Oct 25, 2016·Nature Chemical Biology·Minoru TanakaJames E Bradner
Oct 25, 2016·Nature Chemical Biology·Michael J WaringYi Yao
Feb 15, 2017·Journal of Medicinal Chemistry·Zhiqing LiuJia Zhou
Jul 7, 2017·Journal of Cellular Biochemistry·Mingchen BaShuzhong Cui
Aug 16, 2017·Seminars in Cancer Biology·Aniruddha ChatterjeeMichael R Eccles
Nov 12, 2019·Biochemical and Biophysical Research Communications·Xueyuan ChengWei Jin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis